When the motor symptoms of Parkinson disease (PD) manifest, the underlying pathological processes have already caused irreversible damage. Research breakthroughs in 2013 support the importance of diagnosing PD in the prodromal phase, suggest biomarkers that could help in identifying patients at high risk of PD, and improve upon current deep brain stimulation strategies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cui, G. et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 494, 238–242 (2013).
Lévesque, M. & Parent, A. The striatofugal fiber system in primates: a reevaluation of its organization based on single-axon tracing studies. Proc. Natl Acad. Sci. USA 102, 11888–11893 (2005).
Recasens, A. et al. Lewy body extracts from Parkinson's disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. http://dx.doi.org/10.1002/ana.24066.
Berg, D. et al. Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol. 12, 514–524 (2013).
Kordower, J. H. et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 136, 2419–2431 (2013).
Iranzo, A. et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 12, 443–453 (2013).
Schapira, A. H. et al. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 12, 747–755 (2013).
Schuepbach, W. M. et al. Neurostimulation for Parkinson's disease with early motor complications. N. Engl. J. Med. 368, 610–622 (2013).
Sprenger, F., Seppi, K., Wolf, E. & Poewe, W. Relevance of EARLYSTIM in a tertiary movement disorder center. Mov. Disord. http://dx.doi.org/10.1002/mds.25631.
Little, S. et al. Adaptive deep brain stimulation in advanced Parkinson disease. Ann. Neurol. 74, 449–457 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors have received research grants from Novartis and served as advisory board members for Novartis Pharma France. In addition, F. Tison has served as an advisory board member for Abbott and Addex and W. G. Meissner has served as an advisory board member for Adaptive Neuromodulation. They have received teaching honoraria and travel grants from Boehringer Ingelheim, GlaxoSmithKline, TEVA/Lundbeck, Novartis, and UCB Pharma and W. Meissner has received funding from APTES and PSP-France.
Rights and permissions
About this article
Cite this article
Tison, F., Meissner, W. Diagnosing and treating PD—the earlier the better?. Nat Rev Neurol 10, 65–66 (2014). https://doi.org/10.1038/nrneurol.2013.273
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2013.273